Aspira Women’s Health, Inc. (NASDAQ: AWH) is a specialized diagnostics company focused on non‐invasive testing solutions for women’s reproductive health. The company develops and commercializes proprietary assays designed to detect and monitor conditions such as endometriosis and ovarian cancer. Its flagship offering, EndoCheck®, combines menstrual blood collection with a molecular biomarker panel to aid gynecologists in the early detection of endometrial tissue outside the uterus. In addition, the company markets OvaSure®, a blood‐based test intended to assist in the assessment of ovarian cancer risk among symptomatic women.
Founded in 2008 and rebranded as Aspira Women’s Health in 2023, the company initially began under the name DxNow before narrowing its focus on the women’s health market. Over the years, it has invested in research partnerships with academic institutions to validate its biomarker platforms and has established a CLIA‐certified laboratory in the United States to process patient specimens. Its product portfolio is supported by peer‐reviewed publications and clinical studies that underscore the sensitivity and specificity of its assays for pelvic pain and ovarian cancer indications.
Aspira’s services are primarily offered through direct collaborations with gynecology practices, fertility clinics and oncology centers across the United States. The company’s business model combines in‐office specimen collection kits with centralized laboratory analysis, allowing clinicians to integrate testing seamlessly into routine patient visits. Through strategic physician outreach, digital marketing initiatives and partnerships with key opinion leaders, Aspira continues to expand its commercial footprint and raise awareness of non‐invasive diagnostic alternatives in women’s healthcare.
Under the leadership of Chief Executive Officer Carrie Parkinson, Aspira Women’s Health has emphasized both scientific rigor and market adoption. Parkinson, who joined the company in 2022, brings over two decades of experience in the molecular diagnostics industry, having held senior positions at both start‐ups and multinational firms. Supported by a management team with backgrounds in clinical laboratory operations, regulatory affairs and commercial strategy, the company seeks to address unmet needs in women’s health by advancing accessible, evidence‐based testing solutions.
AI Generated. May Contain Errors.
Free AWH Stock Alerts